Name | Number of supported studies | Average coverage | |
---|---|---|---|
classical monocyte | 11 studies | 27% ± 7% | |
hepatocyte | 5 studies | 64% ± 22% | |
monocyte | 3 studies | 28% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
liver | 3 studies | 40% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 27862.21 | 226 / 226 | 100% | 584.56 | 405 / 406 |
lung | 95% | 179.54 | 547 / 578 | 36% | 1.73 | 416 / 1155 |
kidney | 70% | 60.43 | 62 / 89 | 60% | 1.70 | 542 / 901 |
spleen | 99% | 476.19 | 239 / 241 | 0% | 0 | 0 / 0 |
skin | 71% | 201.09 | 1290 / 1809 | 26% | 0.61 | 123 / 472 |
lymph node | 0% | 0 | 0 / 0 | 86% | 2.26 | 25 / 29 |
peripheral blood | 81% | 1282.33 | 755 / 929 | 0% | 0 | 0 / 0 |
adipose | 78% | 76.06 | 941 / 1204 | 0% | 0 | 0 / 0 |
bladder | 57% | 32.57 | 12 / 21 | 20% | 0.38 | 99 / 504 |
brain | 41% | 26.86 | 1075 / 2642 | 28% | 0.55 | 196 / 705 |
breast | 45% | 26.76 | 205 / 459 | 18% | 0.50 | 205 / 1118 |
intestine | 46% | 28.07 | 443 / 966 | 16% | 1.24 | 86 / 527 |
pancreas | 12% | 6.23 | 38 / 328 | 40% | 2.31 | 72 / 178 |
prostate | 41% | 27.31 | 101 / 245 | 7% | 0.10 | 36 / 502 |
stomach | 28% | 16.29 | 100 / 359 | 15% | 1.67 | 44 / 286 |
thymus | 25% | 12.33 | 161 / 653 | 16% | 0.28 | 95 / 605 |
esophagus | 31% | 17.96 | 448 / 1445 | 9% | 1.57 | 17 / 183 |
uterus | 18% | 8.61 | 31 / 170 | 20% | 0.48 | 93 / 459 |
adrenal gland | 31% | 13.97 | 81 / 258 | 4% | 0.08 | 10 / 230 |
tonsil | 0% | 0 | 0 / 0 | 33% | 1.05 | 15 / 45 |
blood vessel | 32% | 21.45 | 428 / 1335 | 0% | 0 | 0 / 0 |
heart | 17% | 10.49 | 146 / 861 | 0% | 0 | 0 / 0 |
ovary | 9% | 4.62 | 17 / 180 | 5% | 0.08 | 20 / 430 |
muscle | 2% | 0.60 | 13 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.01 | 1 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006897 | Biological process | endocytosis |
GO_0044419 | Biological process | biological process involved in interspecies interaction between organisms |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0044322 | Cellular component | endoplasmic reticulum quality control compartment |
GO_0042806 | Molecular function | fucose binding |
GO_0005537 | Molecular function | D-mannose binding |
GO_0004873 | Molecular function | asialoglycoprotein receptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | ASGR2 |
Protein name | Asialoglycoprotein receptor 2 Asialoglycoprotein receptor 2 (ASGP-R 2) (ASGPR 2) (C-type lectin domain family 4 member H2) (Hepatic lectin H2) (HL-2) Asialoglycoprotein receptor 2 (HBxAg-binding protein) |
Synonyms | CLEC4H2 HBXBP |
Description | FUNCTION: Mediates the endocytosis of plasma glycoproteins to which the terminal sialic acid residue on their complex carbohydrate moieties has been removed. The receptor recognizes terminal galactose and N-acetylgalactosamine units. After ligand binding to the receptor, the resulting complex is internalized and transported to a sorting organelle, where receptor and ligand are disassociated. The receptor then returns to the cell membrane surface. |
Accessions | ENST00000691900.1 ENST00000254850.11 [P07307-3] Q7Z4G9 P07307 ENST00000446679.6 [P07307-2] ENST00000355035.9 [P07307-1] I3L1H2 ENST00000574868.1 |